Colchicine
Colchicine prevents rise in total plaque volume for patients with stable CAD
CHICAGO — Among patients with stable coronary artery disease, colchicine lowered total plaque volume compared with placebo but had no impact on low attenuation plaque volume, researchers reported.
Colchicine curbs cardiovascular event risk when used with urate-lowering therapy for gout
Colchicine for gout flare prophylaxis reduces the risk for cardiovascular events among patients initiating urate-lowering therapy, according to data published in The Lancet Rheumatology.
SGLT2 inhibition reduces need for urate lowering therapies, medical visits in gout
WASHINGTON — SGLT2 inhibitors can reduce the need for urate-lowering and flare therapies, and lower the odds of gout-centric medical visits, in patients with gout alongside type 2 diabetes, according to a speaker at ACR Convergence 2024.
‘Potential added benefit’: Colchicine lowers risk for knee, hip replacement in gout
WASHINGTON — The use of colchicine for gout flare prevention imparts a “modest” decrease in the risk for knee or hip replacement over several years, according to a study presented at ACR Convergence 2024.
In PCI for MI, spironolactone does not meet primary endpoints but may show benefit in HF
CHICAGO — In patients with acute MI who underwent PCI, spironolactone did not improve the primary composite outcomes but was linked to reduced risk for new or worsening HF, according to new data from the CLEAR SYNERGY (OASIS-9) trial.
Top in cardiology: Benefits of colchicine refuted; valve replacement for aortic stenosis
Patients referred for percutaneous coronary intervention after acute myocardial infarction did not experience improved cardiovascular outcomes when taking colchicine compared with placebo, refuting previous study results.
Colchicine does not improve outcomes in patients getting PCI after acute heart attack
WASHINGTON — Contradicting previous research, in a large trial of patients referred for PCI after acute MI, colchicine did not improve CV outcomes compared with placebo, according to the CLEAR SYNERGY (OASIS-9) trial presented at TCT 2024.
FDA approves new label for Gloperba enabling precision dosing for gout prophylaxis
The FDA has approved an updated label for Gloperba, an oral liquid colchicine formulation, allowing for precision dosing, according to a press release from Scilex Holding Company.
Recent flares, starting dose predict gout flare risk in first 6 months of allopurinol
When initiating allopurinol for gout under a “start low, go slow” dosing strategy, flares in the first 6 months are most common in patients starting with 100 mg daily, or who flared in the month before beginning therapy, according to data.
One-quarter of patients with gout receive colchicine despite potential interactions
Approximately 26% of patients with gout are commonly prescribed colchicine prophylaxis despite already using medications with potential interactions, according to data published in Rheumatology.